The vaccination route may influence the success of immunization against pathogens. The conventional intramuscular (i.m.) application of a vaccine containing the hepatitis B virus (HBV) surface antigen (HBsAg) led to protective anti-HBs antibody levels in the majority of vaccine recipients. In this s
Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen-carrier children who cleared serum- hepatitis B surface antigen
β Scribed by H Hsu; M Chang; R Hsieh; Y Ni; W Chi
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 186 KB
- Volume
- 24
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
β¦ Synopsis
Abbreviations: HBsAg, hepatitis B surface antigen; anti-HBs, hepatitis B surface antimonths. 2 From the 415 children, we recruited 16 chronically infected gen antibody; HBV, hepatitis B virus; PCR, polymerase chain reaction; PBMC, peripheral children who had cleared serum HBsAg for more than 2 years. After blood mononuclear cells; rHBsAg, recombinant hepatitis B surface antigen; PHA, phytoheobtaining informed consent from the patients and/or their parents, magglutinin; IL, interleukin; SI, stimulation index; cpm, counts per minute; IFN-g, interwe studied their immune response to HBsAg. There were 10 boys feron gamma; S/N, sample cpm per negative control mean cpm; Th, T helper cell.
From the Departments of 1 Emergency Medicine, 2 Pediatrics, and 3 Laboratory Medicine, and 6 girls, with a mean age of 14.4 years (range, 8-20 years). Of College of Medicine, National Taiwan University and 4 Development Center for Biotechnol-the 16, 11 patients did not develop anti-HBs during the follow-up ogy, Taipei, Taiwan. period of at least 2 years from the time HBsAg disappeared (group
π SIMILAR VOLUMES
## Abstract Antibody to hepatitis B surface antigen (HBsAg) (antiβHBs) can exist in patients with chronic hepatitis B virus (HBV) infection. To date, little is known about the association of concurrent HBsAg and antiβHBs (concurrent HBsAg/ antiβHBs) with hepatocellular carcinoma (HCC). The aim of t
Quantitative hepatitis B surface antigen (qHBsAg) and quantitative hepatitis B e antigen (qHBeAg) titers are emerging as useful tools for measuring viral loads and for predicting the virological response (VR) and serological response (SR) to pegylated interferon therapy. However, the clinical utilit